Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$108.0K+340.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yehiel Tal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Beta
- 0.76
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -30.07
Financials
Revenue
$108.0K+340.7%Net Income
$-2.73MEBITDA
$-2.44MFree Cash Flow
$-2.54MEPS (diluted)
$-1.89Shares Outstanding (diluted)
1.44M+576.5%Operating Expenses
$1.98MCash & Debt
$2.95MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.37M | $-11.49M | $-9.40 |
| 2024 | $515.0K | $-16.61M | $-14.50 |
| 2023 | $10.96M | $-7.02M | $-6.20 |
| 2022 | $299.0K | $-16.93M | $-15.20 |
| 2021 | $15.64M | $237.0K | $0.41 |
| 2020 | $6.14M | $-5.77M | $-8.40 |
| 2019 | $2.32M | $-11.16M | $-29.50 |
| 2018 | $4.79M | $-6.25M | $-14.30 |
| 2017 | $479.9K | $-5.80M | $-22.70 |
| 2016 | $75.9K | $-7.27M | $-36.00 |
| 2015 | $0.00 | $-4.80M | $-28.30 |
| 2014 | $0.00 | $-3.64M | $-20.80 |
| 2013 | $0.00 | $-4.56M | $-45.60 |
| 2012 | $0.00 | $-4.46M | $-53.70 |
Valuation
CLGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (6)
- Newsprnewswire.com·7d ago·Negative
…xisting Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered…
View source ↗ - Newsprnewswire.com·10d ago·Neutral
…nces its Photonic Computing Strategy Through LightSolver's Growing IP Portfolio REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary, LightSolver, has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for an invention that significantly expands the capabilities of its all-optical, laser-based computing platform.
View source ↗ - Newsprnewswire.com·16d ago·Positive
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.
View source ↗ - Newsseekingalpha.com·29d ago·Positive
CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript
View source ↗ - Newsprnewswire.com·36d ago·Neutral
CollPlant to Host LightSolver Investor Webinar on September 17, 2026 REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
View source ↗
Earnings
Wed, Dec 2(in 7 weeks)
Consensus estimate $-0.53 per share
Typical surprise +22.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Sep 30$-1.89 vs $-2.45beat
- Fri, May 29$-0.23 vs $-0.24beat
- Thu, Mar 26$-0.67 vs $-2.98beat
- Wed, Nov 26$-2.70 vs $1.55miss
- Wed, Aug 20$-2.80 vs $-1.00miss
- Wed, May 28$-0.13 vs $-3.70beat
Estimates and results for CLGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLGN officers and directors.
No open-market trades in the recent filings. All 36 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
36 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.